StageAcq - P2P | Acquired
Zalicus, formerly CombinatoRx, is a biopharmaceutical company focused on developing new medicines built from synergistic combinations of approved drugs, designed to attack disease on multiple fronts. CombinatoRx applies its proprietary combination drug discovery technology to identify new combination product candidates in a number of disease areas, including immunoinflammatory disease, oncology, metabolic disease, neurodegenerative disease, and infectious disease.
Missing: Zalicus's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Zalicus's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Expert Collections containing Zalicus
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Zalicus is included in 1 Expert Collection, including Cancer.
Pharmaceutical and biotechnology companies with cancer therapy drug candidates.
Zalicus has filed 9 patents.
Ion channels, Sodium channels, Analgesics, Ion channel toxins, Neurotoxins
Ion channels, Sodium channels, Analgesics, Ion channel toxins, Neurotoxins
Latest Zalicus News
Oct 7, 2015
Kevin Pojasek is president and acting CEO of Quartet Medicines, a new company developing… more Courtesy Atlas An early-stage biotech formed two years ago at Atlas Venture has brought in another $6 million in funding and named two new board members as it works to develop new kinds of treatments for pain and inflammation. Quartet Medicine, which officially launched a year ago with $17 million in Series A funding from Atlas, Novartis Venture Funds, Pfizer Venture Investment and Partners Innovation Fund, has closed that round at $23.25 million. The extra money comes from the Dallas venture firm, Remeditex, and what the company described as “two undisclosed Shanghai-based strategic investors.” Kevin Pojasek is president and acting CEO of Quartet Medicines, a new company developing… more Courtesy Atlas Remeditex CEO John Creecy has joined the board of Quartet, as well as Mark Corrigan , the former CEO of Zalicus , a Cambridge-based company which had been developing a type of drug for chronic pain known as calcium channel modulators. Two years ago, that company’s lead drug failed to show it was better than a placebo in a mid-stage trial, and last year Zalicus merged with a Boston drug company called Epirus Biopharmaceuticals (Nasdaq: EPRS) to focus on making generic versions of biologic drugs. Corrigan serves as chairman of the board of Epirus. Quartet is hoping to avoid the fate of drugs at Zalicus and several others in the field of pain management, which are difficult to prove effective in clinical trials. When I spoke to Quartet’s acting CEO and co-founder Kevin Pojasek a year ago, he explained that the company is targeting a chemical in the body called tetrahydrobiopterin (or BH4), a so-called cofactor which helps certain enzymes to work. Levels of BH4 are tied to pain and inflammation, and Quartets intends to use that as a biomarker to tell how effective its drugs are rather than relying only on the patient’s own subjective reporting. “In closing this financing we deepened our investor base and added the capital required to achieve both our near-term development candidate selection milestone as well as advance our first program through early clinical testing,” said Pojasek in a statement today. The company is located at the Atlas headquarters at 400 Technology Square in Kendall Square. Bizspace Spotlight
Zalicus Frequently Asked Questions (FAQ)
When was Zalicus founded?
Zalicus was founded in 2000.
Where is Zalicus's headquarters?
Zalicus's headquarters is located at 245 First Street, Cambridge.
What is Zalicus's latest funding round?
Zalicus's latest funding round is Acq - P2P.
How much did Zalicus raise?
Zalicus raised a total of $76.4M.
Who are the investors of Zalicus?
Investors of Zalicus include Horizon Discovery, Integral Capital Partners, Bass Companies, Clariden Leu, Domain Associates and 37 more.
Who are Zalicus's competitors?
Competitors of Zalicus include Oligomerix, NGM Biopharmaceuticals, Threshold Pharmaceuticals, Trophos, Neurogen and 12 more.
Compare Zalicus to Competitors
Kemia discovers and develops new, oral small molecule medicines for well-validated, clinically significant targets. Kemia applies proprietary chemistries and medicinal chemistry experience to two large and as yet underdeveloped classes of small molecule drug opportunities -- alpha helix interactions and allosteric kinase inhibitors. These target classes include numerous potential drug discovery targets across major disease areas including inflammation, cancer, HIV, diabetes and bone diseases.
Longevica is a biotechnology that is researching mechanisms of healthy aging and life extension. The company is also developing an open research tool for scientists and research institutions to access a data set that tracks the effects of pharmacological compounds for testing drugs.
BIKAM Pharmaceuticals, Inc. is an early stage biopharmaceutical company focusing upon the discovery and development of small molecule therapeutics for the treatment of ophthalmic diseases and disorders, including retinitis pigmentosa. Worldwide, there are approximately 1.5 million people which suffer from retinitis pigmentosa (RP), a hereditary disease which leads to blindness. As its initial priority, the company is pursuing the discovery of compounds based on a novel mechanism of action identified by the company's founder, Dr. Shalesh Kaushal. BIKAM has an experienced management team with a strong track record in pharmaceutical drug discovery dedicated to expanding these findings and others from the Kaushal lab to create potential therapeutics to prevent blindness.
BioMarck Pharmaceuticals is a biopharmaceutical company dedicated to the discovery and development of drugs for the treatment of pulmonary diseases and disorders associated with the over-secretion of mucus and pulmonary inflammation. In developing its lead compound, BIO-11006 Inhalation Solution, BioMarck has chosen chronic obstructive pulmonary disease (specifically chronic bronchitis) as its first target, but other diseases including asthma, and cystic fibrosis are later disease targets. BIO-11006 Inhalation Solution works by a novel dual mechanism; it inhibits both the secretion of mucus in the lungs and pulmonary inflammation. These aspects of BIO-11006 Inhalation Solution have been demonstrated in several different animal models. In addition, BioMarck has completed a full panel of preclinical safety studies, has an active IND with the FDA, has completed two BIO-11006 in Phase 1 clinical studies, and is currently conducting a Phase 2 study of the efficacy of BIO-11006 in COPD patients.
Spider Biotech is a young and dynamic biotechnology company founded in 2005 with the aim of developing synthetic peptide therapeutics. nnAntimicrobial host-defense peptides have been recognized as an important part of innate immunity found throughout the evolutionary tree that defend against invading bacteria, viruses, and fungi through membrane or metabolic disruption. Inspired by natural antimicrobial peptides, Spider Biotech is developing a library of bioactive peptides and lipopeptides active against bacterial and viral infections. nSpiderBiotech's business strategy is to remain focused on the discovery and early-stage development of drug candidates and seek to establish partnerships with pharmaceutical companies for late-stage development and commercialization of its products. nnThe firm aims to become leader in developing peptide-based antiinfectives to address the urgent and global problem posed by resistance to conventional treatments. The Company is headquartered at the Bioindustry Park del Canavese (Turin, Italy).
Chroma Therapeutics is a biotechnology company founded to exploit the potential of chromatin biology for cancer drug discovery. Chroma is focused on the identification of anti-cancer agents that combine the efficacy of cytotoxics with the tumour cell selectivity of modern targeted therapeutics. Based in Oxford, UK, Chroma is developing a pipeline of anti-cancer drugs.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.